Sivik Global Healthcare LLC Takes $5.18 Million Position in Smith & Nephew plc (NYSE:SNN)

Sivik Global Healthcare LLC acquired a new position in Smith & Nephew plc (NYSE:SNN) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 190,000 shares of the medical equipment provider’s stock, valued at approximately $5,183,000. Smith & Nephew comprises 2.2% of Sivik Global Healthcare LLC’s portfolio, making the stock its 28th biggest holding.

Other hedge funds also recently bought and sold shares of the company. Scharf Investments LLC grew its stake in shares of Smith & Nephew by 20.5% during the 4th quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider’s stock valued at $81,304,000 after purchasing an additional 506,474 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Smith & Nephew by 17.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 36,315 shares of the medical equipment provider’s stock worth $900,000 after purchasing an additional 5,384 shares in the last quarter. Seed Wealth Management Inc. bought a new position in Smith & Nephew in the 4th quarter worth $213,000. London & Capital Asset Management Ltd purchased a new position in Smith & Nephew during the fourth quarter valued at $1,054,000. Finally, American Century Companies Inc. grew its holdings in Smith & Nephew by 343.5% during the third quarter. American Century Companies Inc. now owns 2,364,037 shares of the medical equipment provider’s stock valued at $58,557,000 after purchasing an additional 1,830,965 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew Price Performance

SNN stock traded down $0.47 during trading on Tuesday, reaching $24.14. The company’s stock had a trading volume of 1,173,586 shares, compared to its average volume of 998,784. The company has a quick ratio of 0.72, a current ratio of 1.77 and a debt-to-equity ratio of 0.44. The company’s fifty day moving average is $25.83 and its 200-day moving average is $26.02. The company has a market capitalization of $10.55 billion, a P/E ratio of 11.60, a price-to-earnings-growth ratio of 1.32 and a beta of 0.73. Smith & Nephew plc has a 1 year low of $21.52 and a 1 year high of $32.81.

Smith & Nephew Announces Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 22nd. Investors of record on Tuesday, April 2nd will be given a dividend of $0.462 per share. This represents a dividend yield of 2.8%. The ex-dividend date is Monday, April 1st. Smith & Nephew’s dividend payout ratio is currently 43.27%.

Analysts Set New Price Targets

Separately, StockNews.com raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 15th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.